Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 25, 2011

Lonza to Manufacture Genmab’s Tissue Factor-Targeting Antibody-Drug Conjugate

  • Lonza is to provide Genmab with development and cGMP manufacturing expertise for the latter’s preclinical-stage anticancer antibody-drug conjugate (ADC) candidate targeting tissue factor (TF). Under terms of the deal Lonza will carry out process development and cGMP manufacturing for Genmab’s fully human HuMax-TF™ antibody, which is expressed in Lonza’s GS Gene Expression System. Lonza will then conjugate the naked antibody at its ADC plant to generate the final antibody-drug conjugate.

    The HuMax-TF ADC is currently undergoing preclinical development in collaboration with Seattle Genetics, which has provided the ADC technology. Under terms of the deal Seattle retains opt-in rights to the anti-TF ADC, and also an anti-CD74 ADC program, at completion of Phase I clinical trials. 

    Seattle’s technology combines highly potent cell-killing auristatins, with stable linkers that attach the cytotoxic drug to the antibody. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »